ResMed (NYSE: RMD) reported Q2 EPS of $2.43, $0.11 better than the analyst estimate of $2.32. Revenue for the quarter came in at $1.28 billion versus the consensus estimate of $1.27 billion.

For earnings history and earnings-related data on ResMed (RMD) click here.